Featured Research

from universities, journals, and other organizations

Lyme Disease Receptor Identified In Tick Guts

Date:
November 16, 2004
Source:
Yale University
Summary:
Researchers at Yale School of Medicine have identified a Lyme disease receptor called TROSPA that is used by disease agents to invade ticks.

Researchers at Yale School of Medicine have identified a Lyme disease receptor called TROSPA that is used by disease agents to invade ticks.

Lyme disease, the most common tick-borne disease in the United States, is caused by spirochete bacteria Borrelia burgdorferi, which also cause arthritis in humans. The purpose of the study, published November 12 in the journal Cell, was to identify how Lyme disease pathogens survive inside ticks.

"We identified a receptor inside the tick gut that the spirochete bacteria use to colonize or invade ticks," said principal investigator Erol Fikrig, M.D., professor of internal medicine/rheumatology and in the Section of Microbial Pathogenesis, and Department of Epidemiology and Public Health at Yale School of Medicine. "When we eliminated or blocked the receptor in the ticks, they were no longer able to carry the Lyme disease agent Borellia burgforferi."

"This opens up potential new avenues to disrupt the Borellia's life cycle and offers strategies for improving diagnosis and treatment of Lyme disease," Fikrig added.

To characterize the Lyme disease receptor, the team cloned the gene for the receptor from ticks. After they expressed the purified receptor gene, they showed that the Lyme disease agent Borellia burgforferi binds to the receptor. "When we blocked the receptors with antibodies or when we used RNA interference to knock the receptor out of the ticks, they no longer carried Borellia burgforferi," said Fikrig.

"We are excited to learn more about the life cycle of this important pathogen," Fikrig added. "This information can also be used to study other vector-borne diseases such as West Nile virus and Malaria," Fikrig added.

Other authors on the study included Utpal Pal, Xin Li, Tian Wang, Ruth R. Montgomery, Nandhini Ramamoorthi, Aravinda M. deSilva, Fukai Bao, Xiaofeng Yang, Marc Pypaert, Deepti Pradhan, Fred S. Kantor, Sam Telford and John F. Anderson.

###

Citation: Cell, No. 19 Volume 4, November 12, 2004.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Lyme Disease Receptor Identified In Tick Guts." ScienceDaily. ScienceDaily, 16 November 2004. <www.sciencedaily.com/releases/2004/11/041115003149.htm>.
Yale University. (2004, November 16). Lyme Disease Receptor Identified In Tick Guts. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/11/041115003149.htm
Yale University. "Lyme Disease Receptor Identified In Tick Guts." ScienceDaily. www.sciencedaily.com/releases/2004/11/041115003149.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins